Sector News

Drug companies still supplying Greece after ‘No’ vote

July 6, 2015
Life sciences
(Reuters) – Pharmaceutical companies said on Monday they would continue to supply medicines to Greece for now, despite increased financial uncertainty after Greeks rejected the terms of a rescue package from creditors in a referendum.
 
Drugmakers are owed more than 1.1 billion euros ($1.2 billion) by Greek hospitals and the state-run health insurer, after not being paid since December, but have promised to keep supplying the country on humanitarian grounds.
 
The European Federation of Pharmaceutical Industries and Associations (Efpia), representing 40 drug companies, said it stood by a commitment made last week to ensure supplies continued for the coming month.
 
Imports of life-saving medicines – along with fuel – top the list of products at risk as Greece struggles with bank closures and the threat of an exit from the euro zone. Nearly all Greek medicine is imported.
 
Efpia warned last week, however, that shortages could still emerge on the ground, given the fragmented nature of the Greek supply chain, adding this could be exacerbated if drugs were re-exported.
 
A spokeswoman for AstraZeneca said the company was preparing contingency plans but operations for now were continuing as normal.
 
“At present, there is no impact on our supply chain as, while the banks are closed, bank transfers to and within Greece are still possible,” she said.
 
Pfizer said current recorded stock levels in Greece should ensure that patients did not suffer any interruption in supply to its medicines in the short term.
 
Roche also said both its medicines and diagnostics were currently available to patients. “Roche is working to understand the full implications of yesterday’s referendum decision and will both review and take steps to revise its operating plans as needed,” the company said. 
 
By Ben Hirschler (Additional reporting by Paul Arnold in Zurich; Editing by Susan Fenton)

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach